29 results
Keyword panitumumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Vectibix
panitumumab, Colorectal Neoplasms
Date of authorisation: 03/12/2007, Revision: 33, Authorised, Last updated: 07/12/2021panitumumab … authorisation for Vectibix (panitumumab) Outcome of re-examination … contains the active substance panitumumab. Vectibix is used to treat … -
List item
Human medicine European public assessment report (EPAR): Erbitux
cetuximab, Head and Neck Neoplasms; Colorectal Neoplasms
Date of authorisation: 29/06/2004, Revision: 29, Authorised, Last updated: 25/05/2022 -
List item
Human medicine European public assessment report (EPAR): Lumykras
sotorasib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/01/2022,, Authorised, Last updated: 31/03/2022
-
List item
Human medicine European public assessment report (EPAR): Portrazza
necitumumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 15/02/2016,, Revision: 3, Withdrawn, Last updated: 27/07/2021
-
List item
Human medicine European public assessment report (EPAR): Teysuno
tegafur, gimeracil, oteracil, Stomach Neoplasms
Date of authorisation: 14/03/2011, Revision: 21, Authorised, Last updated: 04/04/2022 -
List item
Human medicine European public assessment report (EPAR): Lonsurf
trifluridine, tipiracil hydrochloride, Colorectal Neoplasms
Date of authorisation: 25/04/2016, Revision: 7, Authorised, Last updated: 13/01/2022 -
List item
Human medicine European public assessment report (EPAR): Breyanzi
CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells), Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Date of authorisation: 04/04/2022,, Authorised, Last updated: 20/05/2022
-
List item
Human medicine European public assessment report (EPAR): Rybrevant
amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021,,
, Authorised, Last updated: 04/02/2022
-
List item
Human medicine European public assessment report (EPAR): Hemlibra
Emicizumab, Hemophilia A
Date of authorisation: 23/02/2018,,
, Revision: 11, Authorised, Last updated: 10/05/2022
-
List item
Human medicine European public assessment report (EPAR): Libtayo
Cemiplimab, Carcinoma, Squamous Cell
Date of authorisation: 28/06/2019,,
, Revision: 11, Authorised, Last updated: 04/02/2022
-
List item
Human medicine European public assessment report (EPAR): Yervoy
Ipilimumab, Melanoma; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Mesothelioma, Malignant; Colorectal Neoplasms
Date of authorisation: 13/07/2011, Revision: 48, Authorised, Last updated: 12/05/2022 -
List item
Human medicine European public assessment report (EPAR): Zirabev
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019,,
, Revision: 10, Authorised, Last updated: 29/03/2022
-
List item
Human medicine European public assessment report (EPAR): Zaltrap
aflibercept, Colorectal Neoplasms
Date of authorisation: 01/02/2013, Revision: 10, Authorised, Last updated: 22/11/2021 -
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms
Date of authorisation: 17/07/2015,, Revision: 46, Authorised, Last updated: 29/06/2022
-
List item
Human medicine European public assessment report (EPAR): Stivarga
regorafenib, Colorectal Neoplasms
Date of authorisation: 26/08/2013, Revision: 17, Authorised, Last updated: 02/12/2021 -
List item
Human medicine European public assessment report (EPAR): Tyverb
lapatinib, Breast Neoplasms
Date of authorisation: 10/06/2008, Revision: 33, Authorised, Last updated: 15/03/2022 -
List item
Human medicine European public assessment report (EPAR): Abevmy
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021,,
, Revision: 3, Authorised, Last updated: 11/04/2022
-
List item
Human medicine European public assessment report (EPAR): Avastin (updated)
bevacizumab, Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 60, Authorised, Last updated: 01/07/2022 -
List item
Human medicine European public assessment report (EPAR): Aybintio
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020,,
, Revision: 4, Authorised, Last updated: 10/09/2021
-
List item
Human medicine European public assessment report (EPAR): Oyavas
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021,,
, Revision: 2, Authorised, Last updated: 17/03/2022
-
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Mesothelioma; Colorectal Neoplasms
Date of authorisation: 19/06/2015, Revision: 49, Authorised, Last updated: 10/05/2022 -
List item
Human medicine European public assessment report (EPAR): Equidacent
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell
Date of authorisation: 24/09/2020,,
, Revision: 3, Withdrawn, Last updated: 25/11/2021
-
List item
Human medicine European public assessment report (EPAR): Alymsys
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021,,
, Revision: 2, Authorised, Last updated: 21/12/2021
-
List item
Human medicine European public assessment report (EPAR): Cyramza
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014, Revision: 12, Authorised, Last updated: 28/01/2022 -
List item
Human medicine European public assessment report (EPAR): Mvasi
bevacizumab, Carcinoma, Renal Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms
Date of authorisation: 15/01/2018,,
, Revision: 11, Authorised, Last updated: 06/09/2021